A novel homozygous mutation (1619delC) in GPIIb gene associated with Glanzmann thrombasthenia, the decay of GPIIb-mRNA and the synthesis of a truncated GPIIb unable to form complex with GPIIIa

Summary

The absence of agonist-induced platelet aggregation and the lack of fibrinogen receptor (GPIIb/IIIa) on the platelet surface demonstrated that the severe hemorrhagic complications of a child of Romany descent were caused by Glanzmann thrombasthenia. DNA sequencing revealed a novel homozygous deletion of a cytosine (1619delC) in the GPIIb gene causing a frameshift and predicting a novel stop codon at position 533 following 24 altered amino acids. Both parents possessed the same deletion in heterozygous form. The amount of GPIIb mRNA in the patient’s platelets was 0.06% of the amount measured in control platelets. Neither GPIIb nor its truncated form could be detected in the platelets of the patient by Western blotting, while a small amount of GPIIIa was demonstrated. Quantitative flow cytometric analysis showed an elevated number of vitronectin receptors, a component of which is GPIIIa, on the patient’s platelets. The surface expression of vitronectin receptor on thrombasthenic, but not on normal platelets was further increased by activation with thrombin receptor agonist peptide. BHK cells transfected with wild type GPIIIa and mutated GPIIb failed to express any mature GPIIb or pro-GPIIb. Immunoprecipitation with a polyclonal antibody recognizing both GPIIb and GPIIIa recovered a 60 kDa truncated form of GPIIb. This band was absent when immunoprecipitation was carried out with an antibody recognizing GPIIIa, suggesting that the truncated protein, lacking calf-1, calf-2 domains and major part of the thigh domain, is unable to form complex with GPIIIa.

Keywords

Fibrinogen receptor - Glanzmann thrombasthenia - glycoprotein IIb mutation - truncated glycoprotein IIb - vitronectin receptor

• References

• 1 Nurden AT, Nurden P. Inheriteddisorders of platelet function. Academic Press: Platelets; 2002: 681-700.
• 2 French DL, Seligsohn U. Platelet glycoprotein IIb/ IIIa receptors and Glanzmann’s thrombasthenia. Arterioscler Thromb Vasc Biol 2000; 20: 607-10.
• 3 French DL. Glanzmann thrombasthenia database. Available at. http://med.mssm.edu/glanzmanndb Updated 03. April 2003
• 4 O’Toole TE, Loftus JC, Plow EF. et al. Efficient surface expression of platelet GPIIb-IIIa requires both subunits. Blood 1989; 74: 14-8.
• 5 Zimrin AB, Eisman R, Vilaire G. et al. Structure of platelet glycoprotein IIIa. A common subunit for two different membrane receptors. J Clin Invest 1988; 81: 1470-5.
• 6 Coller BS, Cheresh DA, Asch E. et al. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 1991; 77: 75-83.
• 7 Grimaldi CM, Chen F, Wu C. et al. Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 1998; 91: 1562-71.
• 8 Poujol C, Nurden AT, Nurden P. Ultrastructural analysis of the distribution of the vitronectin receptor (alpha v beta 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the alphagranule membrane. Br J Haematol 1997; 96: 823-35.
• 9 Rosenberg N, Dardik R, Rosenthal E. et al. Mutations in the alpha IIb and beta3 genes that cause Glanzmann thrombasthenia can be distinguished by a simple procedure using transformed B-lymphocytes. Thromb Haemost 1998; 79: 244-8.
• 10 Muszbek L, Polgár J, Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993; 69: 282-5.
• 11 Pfaffl MW. Anewmathematicalmethod for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: 2003-7.
• 12 Rosenberg N, Yatuv R, Sobolev V. et al. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport fromthe endoplasmic reticulumto the Golgi apparatus. Blood 2003; 101: 4808-15.
• 13 Poncz M, Eisman R, Heidenreich R. et al. Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem 1987; 262: 8476-82.
• 14 Ohno S. (AGCTG) (AGCTG) (AGCTG) (GGGTG) as the primordial sequence of intergenic spacers: the role in immunoglobulin class switch. Differentiation 1981; 18: 65-74.
• 15 Ohno S. Evolution is condemned to rely upon variations of the same theme: the one ancestral sequence for genes and spacers. Perspect Biol Med 1982; 25: 559-72.
• 16 Tao J, Arias-Salgado EG, Gonzales-Manchon C. et al. A novel (288del C) mutation in exon 2 of GPIIb associated with type I Glanzmann’s thrombasthenia. Br J Haematol 2000; 111: 96-103.
• 17 González-Manchón C, Fernández-Pinel M, Arias- Salgado EG. et al. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann’s thrombasthenia: disruption of the 674–687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes. Blood 1999; 93: 866-75.
• 18 Kato A, Yamamoto K, Miyazaki S. et al. Molecular basis for Glanzmann’s thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of Glycoprotein IIb-IIIa complex. Blood 1992; 79: 3212-18.
• 19 Arias-Salgado EG, Tao J, González-Manchón C. et al. Nonsense mutation in exon-19 of GPIIb associated with thrombasthenic phenotype. Failure of GPIIb ( △597–1008) to form stable complexes with GPIIIa. Thromb Haemost 2002; 87: 684-91.
• 20 Holbrook JA, Neu-Yilik G, Hentze MW. et al. Nonsense- mediated decay approaches the clinic. Nat Genet 2004; 36: 801-8.
• 21 Xiao T, Takagi J, Coller BS. et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
• 22 Xiong JP, Stechle T, Goodman SL. et al. Integrins, cations and ligands: making the connection. J Thromb Haemost 2003; 1: 1642-54.
• 23 Calvete GJ. Structures of integrin domains and concerted conformational changes in the bidirectional signaling mechanism of α_IIbβ₃ . Exp Biol Med 2004; 229: 732-44.
• 24 Xiong JP, Stechle T, Diefenbach B. et al. Crystal structure of the extracellular segment of integrin αv β3. Science 2001; 294: 339-45.
• 25 Vinciguerra C, Khelif A, Alemany M. et al. Anonsense mutation in the GPIIb heavy chain (Ser870 →stop) impairs platelet GPIIb-IIIa expression. Br J Haematol 1996; 95: 399-407.
• 26 Frachet P, Duperray A, Delachanal E. et al. Role of the transmembrane and cytoplasmic domains in the assembly and surface exposure of the platelet integrin IIb-IIIa. Biochemistry 1992; 31: 2408-15.
• 27 Bennett JS, Kolodziej MA, Vilaire G. et al. Determinants of the intracellular fate of truncated forms of the platelet glycoproteins IIb and IIIa. J Biol Chem 1993; 268: 3580-5.